Heart Failure With Preserved Ejection Fraction as an Exercise Deficiency Syndrome: JACC Focus Seminar 2/4
Source : https://www.sciencedirect.com/science/article/abs/pii/S0735109722056030?via=ihub
Available online 5 September 2022 Across differing spectrums of cardiac function and cardiac pathologies, there are strong associations between measures of cardiorespiratory fitness and burden of symptoms, quality of life,...
Relevance: Across differing spectrums of cardiac function and cardiac pathologies, there are strong associations between measures of cardiorespiratory fitness and burden of symptoms, quality of life, and prognosis. In this part 2 of a 4-part series, we contend that there is a strong association among physical activity, cardiorespiratory...
Share
Empagliflozin in acute Myocardial Infarction: the EMMY trial - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36036746/
doi: 10.1093/eurheartj/ehac494. Online ahead of print. 1 Medical University of Graz, Department of Internal Medicine, Division of Cardiology, Graz, Austria. 2 Medical University of Graz, Department of Internal Medicine, Division...
Conclusions: In patients with a recent myocardial infarction, empagliflozin was associated with a significantly greater NT-proBNP reduction over 26 weeks, accompanied by a significant improvement in echocardiographic functional and structural parameters.
Share
Renal Effects of Empagliflozin in Patients with Type 2 Diabetes Mellitus - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36045524/
Type 2 diabetes mellitus (T2DM) is one of the main causes of mortality and morbidity worldwide. It leads to various long-term complications such as diabetic nephropathy. Diabetes nephropathy is the...
Conclusions: Sodium-glucose cotransporter 2 inhibitor of empagliflozin is a potent anti-hyperglycemic agent. In addition, it has been shown to have some pharmacologic potentials to provide renoprotective effects in patients with T2DM. In current study, we review the available clinical data on the potential renoprotective effects of this drug...
Share
Renin-angiotensin system blockers-SGLT2 inhibitors-mineralocorticoid receptor antagonists in diabetic kidney disease: A tale of the past two decades! - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36051422/
Several pharmacological agents to prevent the progression of diabetic kidney disease (DKD) have been tested in patients with type 2 diabetes mellitus (T2DM) in the past two decades. With the...
Conclusions: Similar positive findings on renal outcomes were recently reported as a top-line result of the empagliflozin trial in patients with CKD regardless of T2DM. However, the full results of this trial have not yet been published. While the use of older steroidal mineralocorticoid receptor antagonists (MRAs) such as spironolactone in DKD...
Share
PREDICTORS OF CHRONIC HEART FAILURE WITH PRESERVED EJECTION FRACTION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS TREATED WITH EMPAGLIFLOZIN - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36027111/
Currently, it's not well known what factors influenced the incidence of heart failure with preserved ejection (HFpEF) fraction in patients receiving sodium glucose co-transporter 2 inhibitors (SGLT2i). Objective: To evaluate...
Conclusions: Predictors for incidence HFpEF in patients with T2DM were age, diabetes duration, presence of abdominal obesity and galectin-3 levels higher than 10 ng/ml.
Share